NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces the commencement of an investigation of Ocular Therapeutix, Inc. (NASDAQ: OCUL) concerning possible violations of federal securities laws.
On May 5, 2017, Ocular Therapeutix disclosed that the U.S. Food and Drug Administration had found minor issues at its manufacturing plant. However, on July 6, 2017, an article published by Seeking Alpha claimed that Ocular Therapeutix’s management had been misleading investors about manufacturing issues. One of the claims made by the article is that more than 50% of lots manufactured by Ocular Therapeutix contain bad product. Following this news, the price of Ocular Therapeutix shares fell $0.68 per share or over 6% to close at $9.50 per share on July 6, 2017.
If you suffered a loss in Ocular Therapeutix and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/OCUL-Info-Request-Form-176.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.